You are here

Novel treatment for DIC

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL135942-01A1
Agency Tracking Number: R41HL135942
Amount: $222,472.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA17-303
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-08-20
Award End Date (Contract End Date): 2019-07-31
Small Business Information
Houston, TX 77030-3411
United States
DUNS: 079252333
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (713) 794-7775
Business Contact
Phone: (713) 795-0105
Research Institution
HOUSTON, TX 77030-3411
United States

 Nonprofit College or University

Project Summary
Several diseasesincluding endotoxemiaand sepsis can cause disseminated intravascular
coagulationDICDIC can induce the formation of microvascular thrombicausing organ
failure and death in the absence of the appropriate treatmentTo datethere are no drugs to
treat DICand several reagents have been tested buttheir strong doses can lead to severe
bleedingsignificantly diminishing their benefitsA severe insult like systemic inflammation
activates both endothelium and coagulation systemThis is characterized by the increment of
a widespread of fibrin deposition that is a hallmark in DICOur candidate drugthe Aprotein
binds to fibrinIn vitrothe Aprotein delayed fibrin formation and blocked platelet adhesion to
fibrin ogenunder high shear stressImportantlythe Aprotein efficiently reduced the
formation of microvascular thrombosis in two different animal species and models for DICa murine model for endotoxemia induced DICanda pig model for bacteria induced DICNote that the Aprotein was given to the micehours after the insult with endotoxinwhile
the Aprotein was administered to the pigshours after the intravenous inoculation of
bacteriaFurthermorein the murine model the Aprotein prevented organ failureand
markedly improved the survival of the treated miceNotablythe Aprotein had no effect on
platelet aggregation in vitro nor affected the tail bleeding time in miceThe Aims for this STTR
areAimTo determine the pharmacological benefit of the Aprotein on reducing
microvascular thrombosis in a porcine model of bacteria induced sepsisThis aim will
demonstrate that the Aprotein is effective in reducing microvascular thrombosis and proinflammatory markers using a gram positive or gram negative bacteria induced DIC modelAimTo determine the safety of the Aprotein for hemostasisThis aim will investigate the
effect of the Aprotein on hemostasis using large animal modelsIn Phase IIwe will optimize
the production of the candidate productand will perform pharmacokineticpharmacologicaland toxicological studiesFinallywe will perform time window studies using larger animals Narrative
This project will further investigate the beneficial effect of Aprotein in treating
disseminated microvascular thromboses such as disseminated intravascular
coagulationDICas seen in conditions like sepsisDifferent primary disordersincluding sepsisendotoxemiacancerand malariacan cause DIC and currentlythe
management of DIC is restricted to treat the underlying conditionand use of antibiotics
in sepsisThe development of the candidate drug addresses this unmet medical need
by providing a safe and effective novel therapeutic approach

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government